NanoString Technologies, Inc., a privately held provider of life science
tools for translational research and developer of molecular diagnostics,
today announced that it will launch three new products for the nCounter®
Analysis System at the American Association of Cancer Research (AACR)
Annual Meeting 2012, March 31-April 4, in Chicago, Ill. NanoString's
suite of new products accelerates sample throughput for validation
studies, enhances copy number studies using FFPE archival samples, and
provides the latest content for human microRNA assays.
nCounter Plex2 Expression Assay Kit increases the
throughput of the nCounter system four-fold by using barcodes to
multiplex in two dimensions, across both samples and mRNA targets. This
assay allows nCounter users to measure up to 200 targets in up to four
samples in a single tube, thus enabling validation studies with large
sample numbers to be run more much rapidly on the nCounter system.
Researchers can now run 192 samples per day with the standard nCounter
instrumentation and up to 384 samples per day with the addition of a
second prep station. The Plex2 kit provides the same
sensitivity, specificity and FFPE compatibility as NanoString's standard
nCounter Cancer Copy Number Assay Kit enables precise analysis of 86
genes that are commonly amplified or deleted in many cancer types,
including: PIK3CA, AKT, PTEN, BRCA, and MYC. It is optimized for
analysis of FFPE samples and maintains the trademark ease-of-use of all
other nCounter assays.
nCounter Human v2 miRNA Expression Assay Kit updates NanoString's
most popular miRNA expression kit with content from miRBase 18. The kit
allows investigators to profile 800 of the most highly expressed miRNAs
in a single tube without the need for amplification. NanoString's
nCounter miRNA panels are the only products capable of multiplexing
hundreds of miRNAs in a single reaction without amplification, and offer
superior specificity and sensitivity at a lower cost than microarrays
and next-generation sequencing.
"This suite of new products demonstrates our continuing commitment to
providing researchers with powerful tools for probing cancer biology,"
said Barney Saunders, Ph.D., Chief Commercial Officer of NanoString
Technologies. "The nCounter system provides high-throughput,
amplification-free, digital quantification of precious FFPE samples, and
is perfectly suited for large-scale, pathway-based translational
research and biomarker validation."
The nCounter Analysis System is a fully automated, multi-application
digital detection and counting system with a very simple workflow. The
assay kits contain all of the reagents and consumables needed to conduct
an experiment. Minimal sample input requirements and compatibility with
a variety of sample types, including FFPE, make it a particularly
attractive solution for cancer research. NanoString provides assays for
copy number variation, gene expression and miRNA analysis.
NanoString Technologies, Inc.